The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Rubius Therapeutics, Inc(NASDAQ:RUBY)


Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematologic...
Website: http://www.rubiustx.com
Founded: 2014
Full Time Employees: 231 (May 2021)
CEO: Pablo J Cagnoni
Sector: Healthcare
Industry: Biotechnology
Rubius Therapeutics Op Cashflow Per Share ttm
Rubius Therapeutics Free Cashflow Per Share ttm
Rubius Therapeutics Cash Per Share ttm
Rubius Therapeutics (GAAP) P/E ratio ttm
Rubius Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.